(Journal Article): Immunotherapy After Recent-Onset Type 1 Diabetes: Combinatorial Treatment for Achieving Long-Term Remission in Humans?
 
Bresson D, von Herrath M (La Jolla Institute for Allergy and Immunology, Department of Developmental Immunology 3, 10355 Science Center Drive, San Diego, California 92121, USA, matthias(at)liai.org )
 
IN: Rev Diabetic Stud 2004; 1(3)
Impact Factor(s) of Rev Diabetic Stud: 0.125 (2006)

Fulltext:    HTML  PDF

ABSTRACT: Insulin-dependent diabetes mellitus (IDDM), or type 1 diabetes mellitus (TlDM), is one of the most common autoimmune diseases. This chronic disorder is thought to be caused by auto-aggressive T lymphocytes that enter the pancreatic islets of Langerhans, where they destroy the insulin-producing beta cells. Activation of such cells is probably multi-factorial involving a genetic predisposition, environmental triggers such as viruses and perhaps direct damage to the pancreas itself (pancreatic beta-cells), for example, caused by a local pro-inflammatory reaction.

TYPE OF PUBLICATION: Editorial

REFERENCES:

1. Merriman TR, Todd JA. Genetics of autoimmune disease. Curr Opin Immmunol 1995. 7:786-792.
2. Akerblom HK, Vaarala O, Hyoty H, Ilonen J, Knip M. Environmental factors in the etiology of type 1 diabetes. Am J Med Genet 2002. 115:18-29.
3. Bach JF, Koutouzov S, van Endert PM. Are there unique autoantigens triggering auto immune diseases? Immunol Rev 1998. 164:139-155.
4. Liu E, Eisenbarth GS. Type 1A diabetes mellitus-associated autoimmunity. Endocrinol Metab Clin North Am 2002. 31:391-410.
5. Coon B, An LL, Whitton JL, von Herrath MG. DNA immunization to prevent autoimmune diabetes. J Clin Invest 1999. 104:189-194.
6. von Herrath MG. Vaccination to prevent type 1 diabetes. Expert Rev Vaccines 2002. 1:25-28.
7. Li AF, Escher A. Intradermal or oral delivery of GAD-encoding genetic vaccines suppresses type 1 diabetes. DNA Cell Biol 2003. 22:227-232.
8. Daniel D, Wegmann DR. Protection of non-obese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23). Proc Natl Acad Sci U S A 1996. 93:956-960.
9. Martinez NR, Augstein P, Moustakas AK, Papadopoulos GK, Gregori S, Adorini L, Jackson DC, Harrison LC. Disabling an integral CTL epitope allows suppression of autoimmune diabetes by intranasal proinsulin peptide. J Clin Invest 2003. 111:1365-1371.
10. Homann D, Dyrberg T, Petersen J, Oldstone MBA, von Herratll MG. Insulin in oral immune "tolerance": a one-amino acid change in the B chain makes the difference. J Immunol 1999. 163:1833-1838.
11. Narendran P, Mannering SI, Harrison LC. Proinsulin-a pathogenic autoantigen in type 1 diabetes. Autoimmun Rev 2003. 2:204-210.
12. Alleva DG, Gaur A, Jin L, Wegmann D, Gottlieb PA, Pahuja A, Johnson EB, Motheral T, Putnam A, Crowe PD, et al. Immunological characterization and therapeutic activity of an altered-peptide ligand, NBI-6024, based on the immunodominant type 1 diabetes autoantigen insulin B-chain (9-23) peptide. Diabetes 2002. 51:2126-2134.
13. Raz I, Elias D, Avron A, Tamir M, Metzger M, Cohen IR. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet 2001. 358:1749-1753.
14. Zanin-Zhorov A, Nussbaum G, Franitza S, Cohen IR, Lider O. T cells respond to heat shock protein 60 via TLR2: activation of adhesion and inhibition of chemokine receptors. Faseb J 2003. 17:1567-1569.
15. Chatenoud L, Thervet E, Primo J, Bach JF. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci U S A 1994. 91:123-127.
16. Herold KC, Burton JB, Francois F, Poumian-Ruiz E, Glandt M, Bluestone JA. Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1 (Ala-Ala). J Clin Invest 2003. 111:409-418.
17. Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, Gitelman SE, Harlan DM, Xu D, Zivin RA, Bluestone JA. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002. 346:1692-1698.
18. Belghith M, Bluestone JA, Barriot S, Megret J, Bach JF, Chatenoud L. TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med 2003. 9:1202-1208.
19. Chatenoud L. CD3 antibody treatment stimulates the functional capability of regulatory T cells. Novartis Found Symp 2003, 252:279-290.
20. Herold KC, Taylor L. Treatment of type 1 diabetes with anti-CD3 monoclonal antibody: induction of immune regulation? Immunol Res 2003. 28:141-150.